New combo therapy aims to halt return of prostate cancer

NCT ID NCT07150715

First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 26 times

Summary

This study compares two radioactive drugs (225Ac-PSMA-617 and 177Lu-PSMA-617) given together with precise radiation therapy for prostate cancer that has returned and spread to a few spots in the body. About 107 adults with this type of cancer will receive one of the drugs plus targeted radiation. The goal is to see which combination works better at stopping the cancer from growing.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OLIGOMETASTATIC PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • UCLA / Jonsson Comprehensive Cancer Center

    RECRUITING

    Los Angeles, California, 90095, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.